Mark Scholz, MD

Curriculum Vitae [ CV ]

A double board-certified medical oncologist, Mark C. Scholz, MD, serves as medical director of Prostate Oncology Specialists Inc. in Marina del Rey, CA, a medical practice exclusively focused on prostate cancer. He is also the executive director of the Prostate Cancer Research Institute. He received his medical degree from Creighton University in Omaha, NE. Dr. Scholz completed his Internal Medicine internship and Medical Oncology fellowship at University of Southern California Medical Center.

Dr. Scholz is a strong advocate for patient empowerment. He is the co-author of the book Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment or Loss of Potency and has written and produced extensive educational material on the subject of prostate cancer in various media including DVDs, blogs, newsletters and pamphlets. He is an invited guest speaker at prostate cancer conferences and support groups throughout the world. He is also an educational speaker on behalf of Amgen, Dendreon and Sanofi-Aventis.

Dr. Scholz is also a past president and co-founder of the Prostate Cancer Research Institute (PCRI), a non-profit organization dedicated to patient education and research. PCRI clinical research on the topic of hormone therapy has been published in the Journal of Urology, The Prostate, and UROLOGY. The PCRI also provides financial support for research endeavors in the area of active surveillance, prostate imaging, and the development of new tumor markers. Future directions for PCRI research are aimed at enhancing the anticancer function of the immune system, developing treatments to prevent bone metastases, and evaluating the impact of nutritional supplements.

Dr. Scholz served as oncology director at the Memorial Campus of the Centinela Freeman Regional Medical Center from 1996-2001. His current hospital affiliations include St. John’s Health Center, Marina del Rey Hospital. His society memberships include the American Society of Clinical Oncology, American Society of Therapeutic Radiology, American Urologic Associate and European Associate of Urology. He continues as a primary investigator actively supervising a number of ongoing prostate cancer clinical trials and has authored or coauthored over 90 scholarly articles and abstracts in his area of expertise.

SOCIETY MEMBERSHIPS

American College of Physicians
American Medical Association
American Medical Society
American Society of Clinical Oncology
American Society of Therapeutic Radiology
American Urological Association, Affiliate
California Medical Society
European Association of Urology
Los Angeles County Medical Association

Moyad, Mark A., and Mark C. Scholz. “Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial.” Research and Reports in Urology 6 (2014): 71.

Guess, B., M. Scholz, and R. Lam. “Preventing and Treating the Side Effects of Testosterone Inactivating Pharmaceuticals in Men with Prostate Cancer.” Seminars in Preventative and Alternative Medicine (2006).

Scholz, M., and S. Strum. “RE: Recovery of Spontaneous Erectile Function After Nerve-Sparing Radical Retropubic Prostatectomy With and Without Early Intracavernous Injections of Alprostadil.” Letter to the Editor, Journal of Urology 161 (1999): 1914-1915.

Scholz, M., “Safety results of the enzalutamide expanded access program in the U.S. and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.” Abstract. ASCO-GU (2014)

Scholz, M., Johnson, J., Guess, B., and R. Lam. “Extent of Disease on Bone Scan, Baseline Alkaline Phosphatase, and 80% Decline in PSA are the Best Indicators Predicting Long Term Survival in Men with Androgen Independent Prostate Cancer Treated with Ketoconazole and Hydrocortisone.” Abstract. Western AUA (2003).